MA44286A - Formulation pharmaceutique de cinéol et d'amoxicilline - Google Patents
Formulation pharmaceutique de cinéol et d'amoxicillineInfo
- Publication number
- MA44286A MA44286A MA044286A MA44286A MA44286A MA 44286 A MA44286 A MA 44286A MA 044286 A MA044286 A MA 044286A MA 44286 A MA44286 A MA 44286A MA 44286 A MA44286 A MA 44286A
- Authority
- MA
- Morocco
- Prior art keywords
- cineol
- amoxicillin
- pharmaceutical formulation
- formulation
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1655017A FR3052066B1 (fr) | 2016-06-02 | 2016-06-02 | Formulation pharmaceutique de cineol et d'amoxicilline |
| MA39084A MA39084A1 (fr) | 2016-06-02 | 2016-06-02 | Formulation pharmaceutique de cineol et d'amoxicilline |
| MA39085A MA39085B1 (fr) | 2016-06-02 | 2016-06-02 | Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne |
| FR1655018A FR3052065B1 (fr) | 2016-06-02 | 2016-06-02 | Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44286A true MA44286A (fr) | 2019-01-09 |
Family
ID=59399462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044286A MA44286A (fr) | 2016-06-02 | 2017-06-02 | Formulation pharmaceutique de cinéol et d'amoxicilline |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11872216B2 (enExample) |
| EP (1) | EP3463479A2 (enExample) |
| JP (1) | JP7033586B2 (enExample) |
| CN (1) | CN109562182A (enExample) |
| CA (1) | CA3026323A1 (enExample) |
| MA (1) | MA44286A (enExample) |
| SA (1) | SA518400554B1 (enExample) |
| WO (1) | WO2017209588A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017209588A2 (fr) * | 2016-06-02 | 2017-12-07 | Advanced Scientific Developements | Formulation pharmaceutique de cinéol et d'amoxicilline |
| WO2021110915A1 (fr) | 2019-12-04 | 2021-06-10 | Pranarôm International S.A. | Procede de transformation d'une huile essentielle |
| DE202021106639U1 (de) | 2021-10-08 | 2023-01-10 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mit beschränkter Haftung | Neue Therapiekonzepte für die Behandlung von Otitis |
| CN118267361B (zh) * | 2024-05-31 | 2024-08-23 | 潍坊格润药业有限公司 | 一种兽用复方阿莫西林可溶性粉 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102309473A (zh) * | 2003-07-17 | 2012-01-11 | 纽约市哥伦比亚大学托管会 | 含有季铵化合物及精油和/或精油成分的协同组合的抗微生物组合物 |
| WO2006120495A1 (fr) | 2005-05-13 | 2006-11-16 | Advanced Scientific Developements | Composition pharmaceutique comprenant un antiviral, an antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol, le thymol, l’eugenol, le borneol et le carvacrol |
| WO2006120494A1 (fr) | 2005-05-13 | 2006-11-16 | Advanced Scientific Developements | Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l’eugenol, le borneol et les carvacrol |
| WO2006120496A1 (fr) | 2005-05-13 | 2006-11-16 | Advanced Scientific Developements | Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l’ eugenol, le thymol, le borneol, et le carvacrol |
| US20080139526A1 (en) * | 2006-12-06 | 2008-06-12 | Donald Treacy | Modified release dosage forms of amoxicillin |
| DE102006007830A1 (de) * | 2006-02-17 | 2007-08-30 | Grünenthal GmbH | Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure |
| AU2009235426A1 (en) * | 2008-04-09 | 2009-10-15 | Lek Pharmaceuticals D.D. | Granulation of active pharmaceutical ingredients |
| FR2937549B1 (fr) | 2008-10-29 | 2011-04-01 | Centre Nat Rech Scient | Nanoparticules de derives beta-lactamine |
| CN103391774B (zh) * | 2010-12-09 | 2016-09-28 | Septeos公司 | 包含反式-肉桂醛的药物组合物及其在治疗感染中的用途 |
| EP2678004A1 (en) | 2011-02-25 | 2014-01-01 | Eydo Pharma | Nanocapsulation of essential oils for preventing or curing infectious diseases alone or with an antibiotic |
| NZ707855A (en) | 2012-11-06 | 2018-11-30 | Rochal Ind Llc | Delivery of biologically-active agents using volatile, hydrophobic solvents |
| MA35295B1 (fr) | 2012-12-31 | 2014-08-01 | Advanced Scient Developments | Complexe moleculaire detoxifiant et antimicrobien |
| FR3025719A1 (fr) * | 2014-09-15 | 2016-03-18 | Septeos | Antimicrobiens potentialises |
| WO2017209588A2 (fr) * | 2016-06-02 | 2017-12-07 | Advanced Scientific Developements | Formulation pharmaceutique de cinéol et d'amoxicilline |
-
2017
- 2017-06-02 WO PCT/MA2017/000014 patent/WO2017209588A2/fr not_active Ceased
- 2017-06-02 EP EP17743405.7A patent/EP3463479A2/fr active Pending
- 2017-06-02 CA CA3026323A patent/CA3026323A1/fr active Pending
- 2017-06-02 CN CN201780041549.7A patent/CN109562182A/zh active Pending
- 2017-06-02 MA MA044286A patent/MA44286A/fr unknown
- 2017-06-02 US US16/306,262 patent/US11872216B2/en active Active
- 2017-06-02 JP JP2019515760A patent/JP7033586B2/ja active Active
-
2018
- 2018-11-29 SA SA518400554A patent/SA518400554B1/ar unknown
-
2024
- 2024-01-10 US US18/408,636 patent/US20240148702A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3026323A1 (fr) | 2017-12-07 |
| WO2017209588A2 (fr) | 2017-12-07 |
| JP7033586B2 (ja) | 2022-03-10 |
| JP2019521178A (ja) | 2019-07-25 |
| WO2017209588A3 (fr) | 2018-03-15 |
| SA518400554B1 (ar) | 2024-07-29 |
| US11872216B2 (en) | 2024-01-16 |
| US20190255024A1 (en) | 2019-08-22 |
| BR112018074913A2 (pt) | 2019-03-12 |
| EP3463479A2 (fr) | 2019-04-10 |
| US20240148702A1 (en) | 2024-05-09 |
| CN109562182A (zh) | 2019-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3548000A4 (en) | PHARMACEUTICAL COMPOSITIONS OF ATROPINE | |
| PL3717471T3 (pl) | Nowe związki i zawierające je kompozycje farmaceutyczne do leczenia chorób | |
| MA43709A (fr) | Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations | |
| MA46466A (fr) | Formulations pharmaceutiques de protéines à viscosité réduite | |
| EP3402549A4 (en) | MICRONADELE COMPOSITIONS AND METHOD FOR USE THEREOF | |
| EP3603620A4 (en) | LIPOSOME COMPOSITION AND PHARMACEUTICAL COMPOSITION | |
| EP3474844A4 (en) | PHARMACEUTICAL FOR EVAPORATING AND SMOKING | |
| EP3412660A4 (en) | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREWITH | |
| EP3310343A4 (en) | IMPLANTABLE MEDICAMENT DELIVERY COMPOSITIONS AND METHOD FOR USE THEREOF | |
| MA43705A (fr) | Formulation pharmaceutique | |
| EP3302561A4 (en) | COMBINATIONS OF ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODIES | |
| FR3032353B1 (fr) | Composition pharmaceutique et dispositif pour le traitement de la douleur | |
| EP3505161A4 (en) | SUBLINGUAL PHARMACEUTICAL COMPOSITION OF EDARAVON AND (+) - 2-BORNEOL | |
| EP3409660A4 (en) | CYCLOAMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | |
| EP3334719A4 (en) | SUBSTITUTED BENZIMIDAZOLE, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | |
| MA44862A (fr) | Formulations de fulvestrant et méthodes d'utilisation de celles-ci | |
| EP3556771A4 (en) | CLAUDIN-5 ANTIBODIES AND MEDICINAL PRODUCTS THEREOF | |
| MA53466A (fr) | Formulation stable d'anticorps anti-osmr | |
| EP3542821A4 (en) | P53 DEGRADATION INDUCTING MOLECULE AND PHARMACEUTICAL COMPOSITION | |
| MA52587A (fr) | Composés d'azabenzimidazole et produit pharmaceutique | |
| EP3373907A4 (en) | RETARD PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | |
| MA52644A (fr) | Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation | |
| EP3777866A4 (en) | PHARMACEUTICAL COMPOSITION AND ADMINISTRATION THEREOF | |
| MA44286A (fr) | Formulation pharmaceutique de cinéol et d'amoxicilline | |
| EP3773654A4 (en) | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND RELATED METHODS |